From MPox to Smallpox and Beyond: NanoViricides’ NV-387 Could Become the First Truly Broad-Spectrum Antiviral with Massive Market Potential! 
NanoViricides, Inc. (NYSE American: NNVC) is a clinical-stage biotech innovator developing revolutionary broad-spectrum antiviral therapies. NNVC’s lead candidate, NV-387, is advancing through Phase II trials and has shown exceptional efficacy in preclinical models against Influenza, RSV, COVID-19, MPox, and Smallpox, outperforming current treatments like Tamiflu, Remdesivir, and Tecovirimat. NV-387’s unique “empiric therapy” approach could allow doctors to treat respiratory viral infections immediately, without waiting for viral identification, opening a potential $20 billion market. The drug is also being evaluated for MPox in Africa with preliminary regulatory approval, and plans are underway to leverage these studies toward Smallpox treatment under the FDA’s “Animal Rule.” Orphan Drug Designation filings and potential Priority Review Vouchers could provide exclusive market access, regulatory incentives, and substantial revenue opportunities. Beyond NV-387, NNVC is developing NV-HHV-1 for Shingles, Chickenpox, and HSV infections, as well as innovative anti-HIV therapies demonstrating superior efficacy in humanized models. The company’s nanoviricide platform mimics host-cell virus-binding sites, neutralizing viruses while avoiding drug resistance—a mechanism that could apply across dozens of viral diseases, including Ebola, Dengue, and seasonal influenza. With a cGMP manufacturing facility, strong IP portfolio, and strategic milestones set for 2025–2026—including Phase II trial results, IND filings, and orphan drug approvals— NNVC is positioned for long-term growth and shareholder value creation. Discover how NNVC is advancing groundbreaking antiviral solutions and creating multiple avenues for potential shareholder returns in rapidly expanding global markets. | 
